FDA Brief

Warning letters Drugs

FDA warning letter to

TSP Solutions Pte. Ltd.

High riskIssued Oct 22Posted Oct 27Center for Drug Evaluation and Research (CDER)

FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.

What happened

FDA found the violations during a review of records TSP Solutions submitted after FDA's September 9, 2025, request for records. The records did not show adequate finished-product testing for sunscreen active ingredient content, impurities, or microorganisms, and they showed reliance on supplier certificates of analysis without identity testing of incoming components. FDA also found the quality unit did not adequately oversee production, laboratory controls, or stability.

What FDA found

  1. TSP Solutions did not test each batch of sunscreen for active ingredient identity and strength, impurities, or harmful microorganisms before release.

    21 CFR 211.165(a) and 211.165(b)
  2. TSP Solutions did not perform at least one identity test on each incoming component and relied on supplier certificates of analysis without validating the supplier's test results.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. TSP Solutions' quality unit did not ensure adequate production controls, laboratory controls, or an ongoing stability program.

    21 CFR 211.22; 211.100(a); 211.160(b); 211.166(a)

What FDA wants

FDA asks TSP Solutions to respond in writing within 15 business days of receipt, identifying FEI 3023093622 and ATTN: Bryce Hammer, and to address the CGMP violations with full testing plans, retain-sample results, and a review of its material system. FDA also recommends a qualified CGMP consultant and may withhold approvals or continue refusing imports until compliance is confirmed.

Who should pay attention

  • brands that use TSP Solutions as a contract manufacturer for OTC drugs or sunscreens
  • U.S. distributors and retailers selling imported OTC drug products
  • suppliers and buyers relying on TSP Solutions' certificates of analysis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Eurofins SF Analytical Laboratories, Inc.

    FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.

    High risk
  3. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium